236 related articles for article (PubMed ID: 9507824)
1. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.
Levy DA; Swanson DA; Slaton JW; Ellerhorst J; Dinney CP
J Urol; 1998 Apr; 159(4):1168-73. PubMed ID: 9507824
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience.
Matin SF; Madsen LT; Wood CG
Urology; 2006 Sep; 68(3):528-32. PubMed ID: 16979706
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
4. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
8. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma.
Rabets JC; Kaouk J; Fergany A; Finelli A; Gill IS; Novick AC
Urology; 2004 Nov; 64(5):930-4. PubMed ID: 15533480
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
11. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
Krambeck AE; Leibovich BC; Lohse CM; Kwon ED; Zincke H; Blute ML
J Urol; 2006 Nov; 176(5):1990-5; discussion 1995. PubMed ID: 17070231
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery for stage IV renal cell carcinoma.
Bennett RT; Lerner SE; Taub HC; Dutcher JP; Fleischmann J
J Urol; 1995 Jul; 154(1):32-4. PubMed ID: 7776449
[TBL] [Abstract][Full Text] [Related]
13. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?
O'Malley RL; Brewer KA; Hayn MH; Kim HL; Underwood W; Pili R; Schwaab T
Urology; 2011 Sep; 78(3):595-600. PubMed ID: 21777963
[TBL] [Abstract][Full Text] [Related]
14. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
Pantuck AJ; Belldegrun AS; Figlin RA
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
[TBL] [Abstract][Full Text] [Related]
17. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
[TBL] [Abstract][Full Text] [Related]
18. Nephron sparing surgery in patients with metastatic renal cell carcinoma.
Krishnamurthi V; Novick AC; Bukowski R
J Urol; 1996 Jul; 156(1):36-9. PubMed ID: 8648832
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma.
Finelli A; Kaouk JH; Fergany AF; Abreu SC; Novick AC; Gill IS
BJU Int; 2004 Aug; 94(3):291-4. PubMed ID: 15291853
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
Wood CG; Margulis V
Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
